Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy
Jeffrey A. Jones(The Ohio State University), John C. Byrd(The Ohio State University), Steven Coutré(Georgetown University), Kim M. Burns(AbbVie (United States)), Nicholas P. Montalvo(AbbVie (United States)), Paul M. Barr(University of Rochester Medical Center), Rod Humerickhouse(Abbott Fund), Matthew S. Davids(Harvard University), Michael Y. Choi(University of California San Diego), Ming Zhu(AbbVie (United States)), William G. Wierda(University of Maryland, Baltimore), Jalaja Potluri(AbbVie (United States)), Anthony R. Mato(University of Pennsylvania), Todd Busman(Abbott Fund), Nicole Lamanna(Memorial Sloan Kettering Cancer Center)
Cited by 36
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k